Literature DB >> 3707813

The interaction between i.v. theophylline and chronic oral dosing with slow release nifedipine in volunteers.

S H Jackson, K Shah, N M Debbas, A Johnston, C A Peverel-Cooper, P Turner.   

Abstract

Eight healthy volunteers received a 5 min i.v. infusion of lysine theophylline, equivalent to 197 mg anhydrous theophylline, both before (day 1) and during (day 5) steady state chronic oral dosing with slow release nifedipine 20 mg 12 hourly. A theophylline pharmacokinetic profile was performed on day 1 and day 5 and a nifedipine pharmacokinetic profile was performed on day 4 and day 5. The greatest difference in serum theophylline concentrations was seen at the first sampling time (5 min after completion of the infusion) with a mean concentration of 9.9 mg l-1 during nifedipine administration and 14.6 mg l-1 with theophylline alone. Thereafter, the difference fell to approximately 1 mg l-1 until 6 h when they became almost identical. Repeated measures analysis of variance using the theophylline serum concentrations at each of ten time points over 8 h as the repeated measures showed a small but significant effect of nifedipine (F(1,151) = 7.0, P less than 0.01) on serum theophylline concentrations. Mean volume of distribution (V) rose from 0.33 +/- 0.07 to 0.39 +/- 0.06 1 kg-1 corrected body weight (CBW) in the presence of nifedipine (t = 2.23, P = 0.052). Theophylline clearance, area under the curve to 8 h AUC (0-8), area under the curve to infinity AUC (0-infinity) and elimination half-life (t1/2) did not change appreciably. No statistically significant changes in nifedipine pharmacokinetics occurred in the presence of theophylline.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707813      PMCID: PMC1400949          DOI: 10.1111/j.1365-2125.1986.tb05212.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.

Authors:  N M Debbas; S H Jackson; K Shah; S M Abrams; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

2.  SIMP: a computer program in BASIC for nonlinear curve fitting.

Authors:  A Johnston
Journal:  J Pharmacol Methods       Date:  1985-12

3.  Digoxin plasma concentrations and nifedipine.

Authors:  G G Belz; P E Aust; R Munkes
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

4.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

5.  Homogeneous enzyme immunoassay for theophylline in serum and plasma.

Authors:  J Chang; S Gotcher; J B Gushaw
Journal:  Clin Chem       Date:  1982-02       Impact factor: 8.327

6.  Verapamil-digoxin interaction.

Authors:  H O Klein; R Lang; E Di Segni; E Kaplinsky
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

7.  Predictability of theophylline levels.

Authors:  S Melethil; J D Carlson; M T Haug
Journal:  Drug Intell Clin Pharm       Date:  1982-09

8.  Pharmacokinetic interaction between theophylline and erythromycin.

Authors:  A Iliopoulou; M E Aldhous; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

9.  Effect of nifedipine on digoxin kinetics in healthy subjects.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; K Kjaer; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

10.  Theophylline disposition in obesity.

Authors:  P Gal; W J Jusko; A M Yurchak; B A Franklin
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

View more
  9 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.

Authors:  N M Debbas; S H Jackson; K Shah; S M Abrams; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

4.  Effect of nifedipine on serum theophylline concentrations and asthma control.

Authors:  S R Smith; J Wiggins; D E Stableforth; C Skinner; M J Kendall
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

Review 5.  Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.

Authors:  Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar
Journal:  Semin Cancer Biol       Date:  2017-12-30       Impact factor: 15.707

Review 6.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

7.  Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline.

Authors:  R A Robson; J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 8.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

9.  Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.

Authors:  Helen Musther; Katherine L Gill; Manoranjenni Chetty; Amin Rostami-Hodjegan; Malcolm Rowland; Masoud Jamei
Journal:  AAPS J       Date:  2015-06-23       Impact factor: 4.009

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.